Abstract: A separation wall is provided in a frame-like shape along a peripheral edge of a through-hole in a non-display region which is defined to be in an island shape inside a display region and in which the through-hole is formed, the separation wall includes an inner metal layer provided in a frame-like shape on a first inorganic insulating film on a side of the through-hole, and a resin layer provided in a frame-like shape on the first inorganic insulating film and the inner metal layer, and the resin layer includes an inner protrusion portion provided in an eaves shape and protruding from the inner metal layer.

Abstract: A display device includes: a thin film transistor layer including a first inorganic insulating film, a first metal layer, a second inorganic insulating film, a second metal layer, and a flattening resin film layered in order; and a light-emitting element layer. A slit is provided in the first and second inorganic insulating film in a bending portion. A filled resin film fills the slit. On the filled resin film, a plurality of lead wiring lines are provided in the same layer as the second metal layer. At least one lead wiring lines is electrically connected to a first and second lower wiring line provided in the same layer as the first metal layer and extending to a display region side and a terminal portion side via a first and second contact hole formed in a layered film including the second inorganic insulating film and the filled resin film.

Abstract: A display device includes: a base substrate; a thin-film transistor layer provided on the base substrate, a light-emitting element layer provided on the thin-film transistor layer, and a sealing film provided on the light-emitting element. Each of light-emitting elements includes: a first electrode; a functional layer, and a second electrode stacked on top of another in a stated order. The display device includes: a display region; a frame region; and a non-display region. The non-display region includes a through hole. The display device includes a separation wall shaped into a frame and provided to the non-display region along an edge of the through hole. The separation wall includes: a first resin layer, and a first metal layer provided on the first resin layer. The first metal layer includes a first protrusion shaped into a canopy, and protruding from the first resin layer toward the display region.

Abstract: [Problem] To provide a pharmaceutical composition containing a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, which is stable enough to permit its distribution to the market. [Solution] A lyophilized formulation containing; a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, and further containing a neutral salt, a disaccharide, a nonionic surfactant, and a buffer. Such a lyophilized formulation includes, for example, as an active ingredient, a fusion protein comprising an anti-transferrin receptor antibody and human iduronate-2-sulfatase, and further containing sodium chloride as the neutral salt, sucrose as the disaccharide, poloxamer as the nonionic surfactant, and phosphate buffer as the buffer.

Abstract: Disclosed is a stable aqueous pharmaceutical composition or lyophilized pharmaceutical composition comprising a protein as the active ingredient. The pharmaceutical composition comprises a protein having physiological activity and two different nonionic surfactants, including polysorbate 80 and polyoxyethylene(160) polyoxypropylene(30) glycol as the nonionic surfactants, for example, and as optional components, sodium chloride as a neutral salt, sucrose as a disaccharide and citrate buffer as a buffering agent.

Abstract: Aqueous pharmaceutical compositions containing a fusion protein of an antibody and a lysosomal enzyme as an active ingredient, which are stable enough to be marketed, are disclosed. The aqueous pharmaceutical composition, for example, comprises the fusion protein of the antibody and the lysosomal enzyme at a concentration of 0.5 to 20 mg/mL, sodium chloride at a concentration of 0.3 to 1.2 mg/mL, sucrose at a concentration of 50 to 100 mg/mL, a nonionic surfactant at a concentration of 0.15 to 3 mg/mL, a buffer at a concentration of 3 to 30 mM, and is adjusted to pH 5.0 to 7.5.

Abstract: An aqueous preparation containing a protein as an active ingredient which is stable in storage in solution and makes an injection pain reduced is provided. More specifically an aqueous preparation containing a phosphate buffer at a concentration of 1 to 20 mM and a protein as an active ingredient is provided. Further more specifically provided is an aqueous preparation containing a phosphate buffer at a concentration of 1 to 20 mM, human growth hormone as an active ingredient, a poloxamer as a non-ionic surfactant; and phenol as a isotonic agent.

Abstract: An aqueous preparation containing a protein as an active ingredient which is stable in storage in solution and makes an injection pain reduced is provided. More specifically an aqueous preparation containing a phosphate buffer at a concentration of 1 to 20 mM and a protein as an active ingredient is provided. Further more specifically provided is an aqueous preparation containing a phosphate buffer at a concentration of 1 to 20 mM, human growth hormone as an active ingredient, a poloxamer as a non-ionic surfactant; and phenol as a isotonic agent.

Abstract: The present invention discloses an aqueous pharmaceutical composition containing a protein in which serum albumin and growth hormone are linked. The aqueous pharmaceutical composition contains, as an active ingredient, a fusion protein of human serum albumin and human growth hormone; the concentration of the fusion protein is 10-100 mg/mL; the concentration of sucrose is 10-150 mg/mL; the concentration of a nonionic surfactant is 0.15-10 mg/mL; the concentration of a preservative is 0.5-12 mg/mL; the concentration of a buffer is 1-30 mM; and the pH is 5.0-8.0.

Abstract: An aqueous preparation containing a protein as an active ingredient which is stable in storage in solution and makes an injection pain reduced is provided. More specifically an aqueous preparation containing a phosphate buffer at a concentration of 1 to 20 mM and a protein as an active ingredient is provided. Further more specifically provided is an aqueous preparation containing a phosphate buffer at a concentration of 1 to 20 mM, human growth hormone as an active ingredient, a poloxamer as a non-ionic surfactant; and phenol as a isotonic agent.

Abstract: [Problem] To provide a pharmaceutical composition containing a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, which is stable enough to permit its distribution to the market. [Solution] A lyophilized formulation containing; a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, and further containing a neutral salt, a disaccharide, a nonionic surfactant, and a buffer. Such a lyophilized formulation includes, for example, as an active ingredient, a fusion protein comprising an anti-transferrin receptor antibody and human iduronate-2-sulfatase, and further containing sodium chloride as the neutral salt, sucrose as the disaccharide, poloxamer as the nonionic surfactant, and phosphate buffer as the buffer.

Abstract: [Problem] To provide a pharmaceutical composition containing a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, which is stable enough to permit its distribution to the market. [Solution] A lyophilized formulation containing; a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, and further containing a neutral salt, a disaccharide, a nonionic surfactant, and a buffer. Such a lyophilized formulation includes, for example, as an active ingredient, a fusion protein comprising an anti-transferrin receptor antibody and human iduronate-2-sulfatase, and further containing sodium chloride as the neutral salt, sucrose as the disaccharide, poloxamer as the nonionic surfactant, and phosphate buffer as the buffer.

Abstract: Aqueous pharmaceutical compositions containing a fusion protein of an antibody and a lysosomal enzyme as an active ingredient, which are stable enough to be marketed, are disclosed. The aqueous pharmaceutical composition, for example, comprises the fusion protein of the antibody and the lysosomal enzyme at a concentration of 0.5 to 20 mg/mL, sodium chloride at a concentration of 0.3 to 1.2 mg/mL, sucrose at a concentration of 50 to 100 mg/mL, a nonionic surfactant at a concentration of 0.15 to 3 mg/mL, a buffer at a concentration of 3 to 30 mM, and is adjusted to pH 5.0 to 7.5.

Abstract: [Problem] To provide a pharmaceutical composition containing a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, which is stable enough to permit its distribution to the market. [Solution] A lyophilized formulation containing; a fusion protein comprising an antibody and a lysosomal enzyme as an active ingredient, and further containing a neutral salt, a disaccharide, a nonionic surfactant, and a buffer. Such a lyophilized formulation includes, for example, as an active ingredient, a fusion protein comprising an anti-transferrin receptor antibody and human iduronate-2-sulfatase, and further containing sodium chloride as the neutral salt, sucrose as the disaccharide, poloxamer as the nonionic surfactant, and phosphate buffer as the buffer.

Abstract: A reception server receives a formation request for forming an image from a user terminal through a network. A seller forms a digital image based on digital data of an original image, and registers the formed digital image in an art database. The seller informs a requester of the formation request about completion of forming the digital image. The reception server reads out a corresponding digital image from the art database, and displays the read digital image on the user terminal, in response to a request from the user terminal. If a button “OK” is clicked on the user terminal, the reception server executes a predetermined payment process. After it is confirmed that the requester has paid for the requested image, the reception server permits the user terminal to download the digital image. The requester then outputs the digital image, downloaded using the user terminal, using a printer.

Abstract: A circular blank made of a steel plate is lapped onto an Al-based plate in lapped areas of the Al alloy plate and another steel plate. Then, the three members are pressed by a pair of electrodes, and a welding current is allowed to flow between both the electrodes, thereby sequentially performing the melting of a current-supplied portion of the Al alloy plate and a portion near the current-supplied portion, the elimination of a molten portion by a partial bulgy deformation of the blank toward the Al alloy plate, the abutment of the bulgy deformed portion against the steel plate, and the resistance-welding between the bulgy deformed portion and the steel plate.

Abstract: A powder material for use in resistance welding articles of aluminum comprises a mixture of 10-50% by weight of a liquid resin and the remaining proportion of a magnesium powder or a blend of magnesium and aluminum powders. Also a method of resistance welding articles of aluminum comprises the steps of preparing a pasty mixture by mixing in a predetermined amount of a liquid resin having a predetermined initial viscosity, a predetermined amount of a metal powder or a blend of metal and metal oxide powders, and inserting the pasty mixture between the mating weld surfaces of the aluminum articles. Only a small welding force and a low current will be required in producing a resistance weld connection between the aluminum articles with desired strength.

Abstract: An aluminum weldment is produced by resistance-welding aluminum workpieces, and has a nugget formed between the aluminum workpieces which contains more magnesium than the base material of the aluminum workpieces. The nugget contains 5.about.17 wt % of magnesium which forms a solid solution with aluminum.

Abstract: Workpieces of aluminum alloy are resistance-welded while a powdery mixture of magnesium and a metal oxide is being interposed between regions of workpieces of aluminum alloy which are to be joined to each other. The metal oxide may comprise at least one material selected from the group consisting of TiO.sub.2, SiO.sub.2, Cr.sub.2 O.sub.3, MnO.sub.2, Fe.sub.2 O.sub.3, CuO, and Ti.sub.2 O.sub.3 and the powdery mixture may include aluminum powder. The workpieces may be made of aluminum, stainless steel, or the like rather than aluminum alloy.